Grant funds to scientists for tumor and carcinoid tumor and pancreatic of neuroendocrine tumor research

Current article ratings:
Patients / public:healthcare Prof:
The American Association caring for carcinoid Foundation-AACR tumor for cancer research is the recipient of the 2011 grants for tumor and carcinoid tumor and pancreatic of Neuroendokriner tumor research the 2011 Raymond and Beverly Sackler AACR Grants for ileum tumor, carcinoid tumor research.

This grant type mechanisms, created to promote understanding of neuroendocrine tumor in cooperation with the care for tumor and carcinoid Foundation (save) to Raymond and Beverly Sackler Fund for art and science, biology, explain the mechanisms of the currently available therapies and identify new treatment targets for tumor, carcinoid and pancreatic Neuroendocrine tumors.

"The AACR is pleased, the first winners of grants created Fund for the arts and Sciences, two outstanding organizations in cooperation with caring for carcinoid Foundation tumor and the Raymond and Beverly Sackler dedicated to stronger against Neuroendocrine tumors," said Margaret Foti, PhD., m.d. (h.c.), CEO of the American Association for cancer research. "The scientists selected by the selection Committee, get these grants are perform exciting work that has the potential, lead to improved treatment options for these tumors."

Providing protection for tumor, carcinoid Foundation-AACR cancer, carcinoid tumor and pancreatic of Neuroendokriner tumor research: this two year grants of $250,000 ($125,000 per year) support junior and senior researchers as they develop and new ideas and innovative approaches, the direct application and relevance to tumor, carcinoid tumors and pancreatic Neuroendocrine tumors have to study. Xianxin hua, m.d., PhD., associate professor, Abramson Cancer Research Institute, Department of biology cancer, the University of PennsylvaniaHua develop new modalities that useful is the way that regulated by Menin Neuroendocrine tumors, through targeted for the treatment of pancreatic cancer, which is tumor suppressor mutated in patients with the inherited multiple Endocrine Neoplasia (MEN1) type-syndrome.

Hua's lab has found that Menin appears to suppress a pro-proliferative signaling pathway of protein methylation. Because Menin mutations to pancreatic Neuroendocrine tumors are connected his findings raise the possibility the objectives Neuroendocrine tumors essential can be the Menin of regulated pathway for treatment. This project to the crucial role of the cascade Menin regulated in the care of neuroendocrine tumors, to unravel the railway as an important target for therapy for Neuroendocrine tumors. Charles M. Rudin, m.d., PhD., Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center; and Co-Director of upper Aerodigestive cancer program, Johns Hopkins University

Rudin's research group focuses on novel cancer therapies therapeutic development. The therapeutic approaches, which you have been most interested in, is the use of a small RNA virus, selectively infect and certain types of cancer, especially cancer with neuroendocrine functions can destroy. Their funded project Oncolytic will try viral therapy for tumor, carcinoid and other Neuroendocrine tumors, better cancer cells define clinical use in patients with aggressive Neuroendocrine tumors to the following objectives as this virus selectively, such as atypical tumor, carcinoid, and small cell carcinoma. 2011 Raymond and Beverly Sackler AACR Grants for ileum tumor, lead carcinoid tumor research: This grants of two-year $100,000 ($50,000 per year) support basic, translational, clinical or epidemiological research with direct application and relevance to ileal carcinoid tumors. Yanping district Li, PhD, postdoctoral research fellow, Vollum Institute & Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon

The tumor, carcinoid proliferation cAMP Li's project, regulation and function, focusing on the possibility that the hormones and peptides secreted by the tumor, carcinoid tumor proliferative signals to the tumor, carcinoid cells, are also provide a positive feedback loop. The hope is, that this study will show the nature of this positive feedback loop in tumor, carcinoid tumors and identify Epac2 as a novel target for Cancer Therapeutics. Monica ter-Minassian, Sc.D, postdoc, Dana-Farber Cancer Institute; postdoctoral fellow, Harvard School of public health

TER-Minassian project, molecular marker of the result in the ileum, tumor, carcinoid tumor and other NET, focuses on the discovery and carcinoid neuroendocrine tumor survival characterization of molecular and genetic factors affect ileum. She should first define the prognostic importance of traditional factors, including serum biomarkers Chromogranin A and alkaline phosphatase in a large, prospective cohort. She will then identify common inherited genetic variants (single nucleotide polymorphisms) associated to survive and explore potential associations between these genetic variants and outcomes in metastatic patients treated with certain drugs.Source:
Michele sharp
American Association for cancer research